A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
← catalyst calendarNCT06210776 · readout in 560 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
800estimated
Sites
54
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-15 | actual | When the study began enrolling |
| Primary completion | 2028-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- HER2-positive Breast Cancer
- HER2-low Breast Cancer
- Breast Cancer
- Advanced Cancer
Intervention
- Drug: Trastuzumab deruxtecan — also filed as T-DXd
Primary outcome
what the primary-completion date above is the date OFReal World Time to Next Treatment (rwTTNT) in Participants With HER2-positive and HER2-low Unresectable or Metastatic Breast Cancer
measured Assessed over a 36-month period
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed